Related Experiment Video

Updated: Feb 26, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K

Effect of Bicyclol Tablets on Drug Induced Liver Injuries after Kidney Transplantation

Wenjun Shang1, Yonghua Feng1, Jinfeng Li1

  • 1Department of Kidney Transplantation, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.

Open Medicine (Warsaw, Poland)
|July 22, 2017
PubMed

Insights

Preventive use of Bicyclol significantly reduced drug-induced liver injuries in kidney transplant patients. This liver-protective treatment offers a promising strategy for early post-transplant care.

Area of Science:

  • Nephrology
  • Hepatology
  • Pharmacology

Background:

  • Liver injury is a frequent complication following kidney transplantation.
  • Drug-induced liver injuries (DILI) pose a significant risk in post-transplant patients.
  • Bicyclol exhibits known anti-inflammatory and hepatoprotective properties.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic Bicyclol in preventing early-stage DILI after kidney transplantation.
  • To assess the clinical impact of Bicyclol on liver protection in this patient population.

Main Methods:

  • A prospective study involving 1600 kidney transplant recipients.
  • Patients were divided into a prevention group (received Bicyclol) and a control group (no hepatic protectors).
  • Analysis focused on the incidence of liver injury and influencing factors in the early post-operative period.

Main Results:

  • Out of 745 analyzed cases, 82 developed liver injuries.
  • The prevention group showed a significantly lower incidence of liver injury (4.82%) compared to the control group (20.76%) (P=0.001).
  • Adjusted odds ratio for the prevention group was 0.197 (95% CI: 0.116, 0.334), indicating a protective effect.

Conclusions:

  • Prophylactic Bicyclol administration is an effective protective factor against early-stage DILI in kidney transplant recipients.
  • Bicyclol demonstrates significant clinical benefit in preventing liver injury post-transplantation.
  • This study supports the use of Bicyclol as a liver-protective strategy in kidney transplant patients.
Keywords:
BicyclolDrug-Induced Liver InjuryImmunosuppressive AgentsKidney TransplantationRetrospective Studies

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.4K
Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells06:23

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells

Published on: November 21, 2025

558

Related Concept Videos

Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
298
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
266
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
312
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.0K